Form D · Pharmaceuticals
HYPERION THERAPEUTICS INC
Brisbane, CA · CIK 0001386858
Offering snapshot reported Jun 18, 2014 · SEC filing
- Reported sold
- $7.99M Offering amount: $7.99M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 12, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 18, 2014 | Initial | $7,990,674 | No comparison | 0 | SEC filing |
| Nov 4, 2011 | Initial | $7,500,749 | No comparison | 10 | SEC filing |
| Apr 18, 2011 | Initial | $17,471,998 | No comparison | 10 | SEC filing |
| Jul 16, 2009 | Initial | $21,981,863 | No comparison | 9 | SEC filing |
| May 14, 2009 | Initial | $12,988,762 | No comparison | Not reported | SEC filing |
| Mar 7, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Oct 5, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Sep 10, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Aug 10, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jan 22, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jan 5, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-219438
Source: Form D, filed Jun 18, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gaurav Aggarwal | Director |
| Dion Coakley | Executive |
| Klara A. Dickinson | Executive |
| Jeffrey S. Farrow | Executive |
| Ashley Gould | Executive |
| David Gryska | Director |
| Bo Jesper Hansen | Director |
| Bo Jesper Hansen | Director |
| Jim Healy | Director |
| James I. Healy | Director |
| Natalie Holles | Executive |
| Robert Hopfner | Director |
| Rob Hopfner | Director |
| Toni Martinez | Executive |
| Masoud Mokhtarani | Executive |
| Christine A. Nash | Executive |
| Jake R. Nunn | Director |
| Daniel Perez | Director |
| Bijan Salehizadeh | Director |
| Donald J. Santel | Executive |
| Don Santel | Executive |
| Bruce F. Scharschmidt | Executive |
| Daniel G. Welch | Director |
| Lota S. Zoth | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2000 Sierra Point Parkway Suite 400
Brisbane, CA, 94005
Brisbane, CA, 94005